Hematology
Refine Search
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Biotechnology
Privately-held Remedy Plan Therapeutics, a US pharma company developing novel, hyperbolic NAMPT inhibitors, has raised more than $18 million in an oversubscribed insider financing round. 13 May 2025
Biotechnology
Genmab posted a 19% rise in revenue to $715 million for the first quarter of 2025, driven by higher royalties and increasing sales of its lymphoma therapy Epkinly (epcoritamab). Earnings before interest and taxes rose to $188 million, up from $116 million a year earlier. 9 May 2025
Pharmaceutical
US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years. 7 May 2025
Biotechnology
Sino American biotech BeiGene, a global oncology company that will change its name to BeOne Medicines, today announced financial results and corporate updates from the first quarter 2025. 7 May 2025
Biotechnology
Priothera today announced the appointment of Jens Hasskarl, as its chief medical officer (CMO). 6 May 2025
Biotechnology
Sweden’s Mendus, a clinical-stage drug developer, has announced the appointment of Dr Tariq Mughal as chief medical officer, effective today, May 5. 5 May 2025
Pharmaceutical
UK drugmaker GSK ended Tuesday’s trading more than 2% higher after announcing its first-quarter financial results. 1 May 2025
Biotechnology
Regeneron Pharmaceuticals today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma. 28 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional marketing authorization for the Aucatzyl (obecabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 28 April 2025
Biotechnology
Chinese biotech LTZ Therapeutics has closed an oversubscribed series A+ financing round, raising $40 million to support its push into early-stage clinical development. 25 April 2025
Pharmaceutical
Swiss pharma giant Roche today reported that it achieved sales growth of 6% (7% in francs) to 15.4 billion francs ($18.8 billion) for the first three months of 2025. That topped projections for $18.34 billion, according to FactSet. 24 April 2025
Pharmaceutical
Bristol Myers Squibb beat Wall Street expectations in the first quarter of 2025, sending shares higher in early trading Thursday, as the company raised its full-year forecast on the back of favorable foreign exchange and solid performance from its newer medicines. 24 April 2025
Pharmaceutical
French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its share price remained unchanged near close. 24 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi (marstacimab) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35kg with hemophilia A and B. 22 April 2025
Pharmaceutical
UK pharm major GSK has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in the pharmaceutical industry, the trade group’s Prescription Medicines Code of Practice Authority (PMCPA) has revealed. 16 April 2025
Biotechnology
Johnson & Johnson has announced new data from an analysis modelling long-term progression free survival (PFS) in transplant eligible (TE) and transplant ineligible (TIE) newly diagnosed multiple myeloma (NDMM) patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). 11 April 2025
Biotechnology
Solu Therapeutics, a US biotech developing therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas, has announced the successful completion of a $41 million Series A financing. 10 April 2025
Biosimilars
Israel-based Teva Pharmaceuticals industries today revealed two important updates reflecting its commitment to expanding access to both biosimilars and innovative medicines. 7 April 2025
Biotechnology
The European Commission (EC) has approved an indication extension of Darzalex (daratumumab) subcutaneous (SC) formulation in the frontline setting. 7 April 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending the use Breyanzi (lisocabtagene maraleucel) for National Health Service (NHS) in England. 21 February 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to treat and prevent bleeding in patients aged two years and above with severe or moderate hemophilia A. 18 February 2025
Pharmaceutical
USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 years with pyruvate kinase (PK) deficiency who are not regularly transfused achieved its primary endpoint of hemoglobin response. 14 February 2025
Pharmaceutical
Antengene has announced that its multiple myeloma treatment, Xpovio (selinexor), will be included in Taiwan’s National Health Insurance (NHI) reimbursement scheme. 13 February 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in yet another indication, US pharma giant Pfizer announced late yesterday. 13 February 2025
Biotechnology
IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T cell therapy being tested in patients with acute myeloid leukemia (AML). 12 February 2025
Biotechnology
US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary endpoint in the marginal zone lymphoma (MZL) cohort. 11 February 2025
Biotechnology
Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International Region at Gilead and Kite Oncology. Mr Santoro outlines the company’s efforts to expand access to innovative CAR T-cell therapies in the Middle East. 8 February 2025
Biotechnology
Biotech firm CSL Behring has announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec) for adults living with hemophilia B. 7 February 2025
Pharmaceutical
Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with hemophilia A with and without inhibitors. 7 February 2025
Biosimilars
Dr Reddy’s Laboratories has signed a licensing deal with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar of Johnson & Johnson’s Darzalex (daratumumab) for multiple myeloma. 7 February 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca beat analyst expectations in presenting its impressive latest financial results. 6 February 2025
Biotechnology
Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO), have announced a strategic partnership to enhance the production of Eleva's pipeline products. 4 February 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its January 2025 meeting, as well as some biosimilars. 31 January 2025
Pharmaceutical
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that the US Food and Drug Administration (FDA) has approved Journavx (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. 31 January 2025
Biotechnology
US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it has elected to discontinue FIRCE-1, a Phase II clinical study of firicabtagene autoleucel (firi-cel). 31 January 2025
Biotechnology
The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL). 30 January 2025
Pharmaceutical
Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange rates (3% in francs) to 60.5 billion francs ($66.9 billion). 30 January 2025
Pharmaceutical
Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back seat to the news that the group’s long-term chief executive Christophe Weber is to retire in 2026. 30 January 2025
Biotechnology
Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Sarclisa (isatuximab) alongside bortezomib, lenalidomide, and dexamethasone (VRd), for newly-diagnosed multiple myeloma patients (NDMM) ineligible for autologous stem cell transplant (ASCT). 29 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze